ABC | Volume 111, Nº6, Dezembro 2018

Artigo Original Radaelli et al Estatinas para tratar crianças: uma meta-análise Arq Bras Cardiol. 2018; 111(6):810-821 Apêndice I Estratégia de busca no PubMed #1. Search (Child OR Adolescent) #2. Search (HypercholesterolemiaOR StatinORDyslipidemias ORCholesterol OR Hydroxymethylglutaryl-CoA Reductase inhibitors) #3. Search (randomized controlled trial[pt] OR controlled clinical trial[pt] OR randomized controlled trials[mh] OR random allocation [mh] OR double- blind method[mh] OR single-blind method[mh] OR clinical trial[pt] OR clinical trials[mh] OR (“clinical trial”[tw]) OR ((singl*[tw] OR doubl*[tw] OR trebl*[tw] OR tripl*[tw]) AND (mask*[tw] OR blind*[tw])) OR (“latin quare”[tw]) OR placebos[mh] OR placebo*[tw] OR random*[tw] OR research design[mh:noexp] OR comparative studies[mh] OR evaluation studies[mh]OR follow-upstudies[mh]ORprospectivestudies[mh]ORcross- over studies[mh] OR control* [tw] OR prospectiv*[tw] OR olunteer*[tw]) NOT (animal[mh] NOT human[mh]) #4. Search (#1 AND #2 AND #3) Apêndice II Apêndice 2 – Gráfico mostrando o efeito da terapia com estatinas nos níveis de colesterol total. 44 44 44 26 26 106 106 126 126 106 63 63 18 18 63 17 35 35 90 24 140 106 1424 1053 15 27 27 108 47 15 16 27 69 69 69 59 6 19 19 120 120 88 6 6 61 60 183,00 293,00 308,90 293,20 293,00 281,15 293,00 308,90 279,76 285,62 321,30 308,90 306,00 308,70 294,69 277,70 300,40 294,69 294,69 318,15 275,80 200,20 210,15 208,70 194,00 195,00 194,09 207,00 224,60 199,50 206,00 257,58 246,00 246,00 251,22 239,08 223,60 246,80 243,34 243,57 276,66 237,60 167,02 179,84 36,00 41,60 44,00 49,98 37,00 43,60 48,62 47,82 6,06 35,60 43,00 6,06 7,68 46,10 62,10 8,41 8,33 6,06 54,60 3,75 3,67 3,10 18,28 58,70 8,89 18,28 56,74 17,44 58,70 57,10 56,69 7,07 58,70 39,00 7,07 5,70 46,10 56,00 5,70 5,70 7,07 53,70 3,79 3,76 –110,00 –100,20 –99,20 –98,00 –87,06 –86,00 –84,30 –80,26 –79,62 –63,72 –62,90 –60,00 –57,48 –55,61 –54,10 –53,60 –51,35 –51,12 –41,49 –38,20 –33,18 –30,31 –66,41 4,6% 3,5% 4,5% 4,4% 4,4% 4,4% 4,5% 5,2% 3,6% 3,3% 4,8% 5,2% 5,1% 5,1% 5,1% 5,2% 5,2% 5,2% 3,7% 4,6% 3,5% 5,2% 100% [–124,10; –95,90] [–127,90; –72,50] [–101,79; –96,61] [–113,96; –82,04] [–103,48; –70,64] [–100,08; –71,92] [–112,07; –56,53] [–96,61; –63,91] [–95,80; –63,44] [–66,05; –61,39] [–88,93; –36,87] [–71,00; –49,00] [–59,82; –55,14] [–61,39; –49,83] [–79,85; –28,35] [–70,96; –36,24] [–57,41; –45,29] [–57,09; –45,15] [–43,81; –39,17] [–68,37; –8,03] [–34,12; –32,24] [–31,24; –29,38] [–75,52; –57,30] –100 100 –50 0 50 Avis 2010, Rosuvastatina 20 mg Avis 2010, Rosuvastatina 10 mg Avis 2010, Rosuvastatina 5 mg de Jongh 2002, Simvastatina 40 mg de Jongh 2002, Simvastatina 20 mg de Jongh 2002, Simvastatina 10 mg Stein 1999, Lovastatina 20 mg Stein 1999, Lovastatina 40 mg Stein 1999, Lovastatina 10 mg Knipscheer 1996, Pravastatina 20 mg Clauss 2005, Lovastatina 40 mg Clauss 2005, Lovastatina 20 mg Van der Graff 2008, Simvastatina 40 mg/Ezetimibe 10 mg Van der Graff 2008, Simvastatina 10 mg–20 mg–40 mg/Ezetimibe 10 mg Rodenburg 2006, Pravastatina 40 mg Knipscheer 1996, Pravastatina 10 mg Knipscheer 1996, Pravastatina 5 mg Braamskamp 2015, Pitavastatina 4 mg Braamskamp 2015, Pitavastatina 2 mg Braamskamp 2015, Pitavastatina 1 mg Weigman 2004, Pitavastatina 20 mg–40 mg McCrindle 2003,Atorvastatina 10 mg–20 mg Heterogeneidade: I 2 = 99,4%, tau 2 = 417, p < 0,0001 Modelo de efeitos aleatórios Estudo Total Total DP DP Diferença média Estatinas Placebo Média Média MD W (aleatório) IC95% 819